Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
(August 25, 2021) – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced positive results from the Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations. The trial demonstrated superior “Good On” time at the conclusion of a 13-week double-blind treatment period. Amneal plans to submit a New Drug Application (NDA) for IPX-203 with the U.S. Food and Drug Administration (FDA) in mid-2022. Click here to learn more about Amneal and IPX-203.